Protecting the heart during breast cancer treatment
Treatments studied
Part of Cancer, Heart & circulation, Injuries & trauma, Skin clinical trials.
This trial tests whether a diabetes medicine (SGLT2 inhibitor) can prevent heart damage caused by a common chemotherapy drug (anthracycline) in people with early-stage breast cancer. If you are newly diagnosed and about to start chemotherapy or have surgery, this study may be for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are over 18 years old.
- You have been diagnosed with localized (early-stage) breast cancer.
- You have not had chemotherapy, targeted therapy, or immunotherapy before.
- You are not currently taking an SGLT2 inhibitor (a type of diabetes drug) or certain blood pressure medicines (ACE inhibitors or ARBs).
- You do not have known heart disease, serious kidney disease, or serious liver problems.
- You are not pregnant, breastfeeding, or receiving treatment for another cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses heart imaging scans and blood tests to check if a common cancer drug (anthracycline) is affecting your heart during treatment. Early detection might help doctors protect your heart health.
This trial tests whether two different medications (SGLT-2 inhibitor vs. DPP-4 inhibitor) can help prevent heart damage from certain chemotherapy drugs (anthracyclines) in women with breast cancer. It aims to protect your heart while you undergo cancer treatment.
This trial checks how well the heart handles anthracycline chemotherapy in breast cancer patients. It helps doctors find early signs of heart side effects so they can keep you safe during treatment.
This trial tests if a heart-protecting drug called dapagliflozin can help prevent heart damage in breast cancer patients receiving a type of chemotherapy called anthracycline. It may be an option if you have low to medium heart risk factors.
This trial tests if the diabetes drug dapagliflozin can protect the heart in people with breast cancer receiving a type of chemotherapy called anthracyclines. You may be able to join if you are between 18 and 80, have stage I-III breast cancer, and are about to start anthracycline treatment within the next 60 days.
This trial tests if the drug dapagliflozin can prevent heart damage caused by anthracycline chemotherapy in breast cancer patients. It aims to see if taking the drug during chemo helps keep your heart healthy.
Hear when a new Breast Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.